Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
出版年份 2018 全文链接
标题
Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016
作者
关键词
-
出版物
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 178, Issue 3, Pages 265-276
出版商
Bioscientifica
发表日期
2018-01-13
DOI
10.1530/eje-17-0933
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas
- (2017) Hélène Lasolle et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas
- (2017) Gerald Raverot et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Diagnosis and Treatment of Pituitary Adenomas
- (2017) Mark E. Molitch JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risk of Recurrence in Pituitary Neuroendocrine Tumors: A Prospective Study Using a Five-Tiered Classification
- (2017) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful treatment of pituitary carcinoma with concurrent radiation, temozolomide, and bevacizumab after resection
- (2017) Waseem Touma et al. JOURNAL OF CLINICAL NEUROSCIENCE
- Aggressive Pituitary Adenomas: The Dark Side of the Moon
- (2017) Stefano M. Priola et al. World Neurosurgery
- Growth hormone–secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog 90Y-DOTATATE: case report
- (2016) Joanna Waligórska-Stachura et al. JOURNAL OF NEUROSURGERY
- Radiotherapy with concurrent temozolomide for the management of extraneural metastases in pituitary carcinoma
- (2016) Carlos Kamiya-Matsuoka et al. Pituitary
- O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents
- (2015) T Walter et al. BRITISH JOURNAL OF CANCER
- Long-Term Outcome and MGMT as a Predictive Marker in 24 Patients With Atypical Pituitary Adenomas and Pituitary Carcinomas Given Treatment With Temozolomide
- (2015) Daniel Bengtsson et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide therapy in patients with aggressive pituitary adenomas or carcinomas
- (2015) Marco Losa et al. JOURNAL OF NEURO-ONCOLOGY
- Aggressive pituitary adenomas—diagnosis and emerging treatments
- (2014) Antonio Di Ieva et al. Nature Reviews Endocrinology
- A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case–control study of 410 patients with 8 years post-operative follow-up
- (2013) Jacqueline Trouillas et al. ACTA NEUROPATHOLOGICA
- DNA Mismatch Repair Protein (MSH6) Correlated With the Responses of Atypical Pituitary Adenomas and Pituitary Carcinomas to Temozolomide: The National Cooperative Study by the Japan Society for Hypothalamic and Pituitary Tumors
- (2013) Toshio Hirohata et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
- (2013) Mark R. Gilbert et al. JOURNAL OF CLINICAL ONCOLOGY
- High Response Rates and Prolonged Survival in Patients With Corticotroph Pituitary Tumors and Refractory Cushing Disease From Capecitabine and Temozolomide (CAPTEM)
- (2013) Brad E. Zacharia et al. NEUROSURGERY
- Peptide receptor radionuclide therapy in a patient with disabling non-functioning pituitary adenoma
- (2013) Jan Komor et al. Pituitary
- Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation
- (2013) Jillian Maclean et al. Pituitary
- First demonstration of the effectiveness of peptide receptor radionuclide therapy (PRRT) with 111In-DTPA-octreotide in a giant PRL-secreting pituitary adenoma resistant to conventional treatment
- (2012) S. Baldari et al. Pituitary
- Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status
- (2011) Ann I. McCormack et al. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
- Pituitary Carcinoma: Difficult Diagnosis and Treatment
- (2011) Anthony P. Heaney JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Mechanism of Acquiring Temozolomide Resistance During Transformation of Atypical Prolactinoma Into Prolactin-Producing Pituitary Carcinoma: Case Report
- (2011) Mineko Murakami et al. NEUROSURGERY
- O-6-Methylguanine-DNA Methyltransferase (MGMT) Immunohistochemical Expression in Pituitary Corticotroph Adenomas
- (2011) Fateme Salehi et al. NEUROSURGERY
- New targeted therapies in pituitary carcinoma resistant to temozolomide
- (2011) Emmanuel Jouanneau et al. Pituitary
- Temozolomide Treatment for Aggressive Pituitary Tumors: Correlation of Clinical Outcome with O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation and Expression
- (2010) Zachary M. Bush et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide Treatment in Aggressive Pituitary Tumors and Pituitary Carcinomas: A French Multicenter Experience
- (2010) Gérald Raverot et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy
- (2009) C Hagen et al. EUROPEAN JOURNAL OF ENDOCRINOLOGY
- Radiosensitizing Effects of Temozolomide Observed in vivo only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts
- (2009) Brett L. Carlson et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Evolution of an Aggressive Prolactinoma into a Growth Hormone Secreting Pituitary Tumor Coincident with GNAS Gene Mutation
- (2009) Andrea G. Lania et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- In vitro and In vivo Radiosensitization Induced by the DNA Methylating Agent Temozolomide
- (2008) W. J. Kil et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started